This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

SGLT-2i key considerations guide

Key considerations when prescribing SGLT-2 inhibitors

Prescribing Information

View our SGLT-2i considerations guide, and learn more about the key considerations when prescribing SGLT-2is to people with Type 2 diabetes.

Supporting documentation

STEGLATRO® (ertugliflozin) 5 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

STEGLATRO® (ertugliflozin) 15 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-STE-00190 | Date of Preparation: June 2019